Search

Your search keyword '"Ghimenti, C"' showing total 104 results
Start Over Author "Ghimenti, C"
104 results on '"Ghimenti, C"'

2. LncRNAs as novel indicators of patients' prognosis in stage i epithelial ovarian cancer: A retrospective and multicentric study

Author

Martini, P, Paracchini, L, Caratti, G, Mello-Grand, M, Fruscio, R, Beltrame, L, Calura, E, Sales, G, Ravaggi, A, Bignotti, E, Odicino, F, Sartori, E, Perego, P, Katsaros, D, Craparotta, I, Chiorino, G, Cagnin, S, Mannarino, L, Ceppi, L, Mangioni, C, Ghimenti, C, D'Incalci, M, Marchini, S, Romualdi, C, Martini, P, Paracchini, L, Caratti, G, Mello-Grand, M, Fruscio, R, Beltrame, L, Calura, E, Sales, G, Ravaggi, A, Bignotti, E, Odicino, F, Sartori, E, Perego, P, Katsaros, D, Craparotta, I, Chiorino, G, Cagnin, S, Mannarino, L, Ceppi, L, Mangioni, C, Ghimenti, C, D'Incalci, M, Marchini, S, and Romualdi, C

Abstract

Purpose: Stage I epithelial ovarian cancer (EOC) represents about 10% of all EOCs and is characterized by good prognosis with fewer than 20% of patients relapsing. As it occurs less frequently than advanced-stage EOC, its molecular features have not been thoroughly investigated. We have demonstrated that in stage I EOC miR-200c-3p can predict patients' outcome. In the present study, we analyzed the expression of long non-coding RNAs (lncRNA) to enable potential definition of a non-coding transcriptional signature with prognostic relevance for stage I EOC. Experimental Design: 202 snap-frozen stage I EOC tumor biopsies, 47 of which relapsed, were gathered together from three independent tumor tissue collections and subdivided into a training set (n = 73) and a validation set (n = 129). Median follow up was 9 years. LncRNAs' expression profiles were correlated in univariate and multivariate analysis with overall survival (OS) and progression-free survival (PFS). Results: The expression of lnc-SERTAD2-3, lnc-SOX4-1, lnc- HRCT1-1, and PVT1 was associated in univariate and multivariate analyses with relapse and poor outcome in both training and validation sets (P < 0.001). Using the expression profiles of PVT1, lnc-SERTAD2-3, and miR-200c-3p simultaneously, it was possible to stratify patients into high and low risk. The OS for high- and low-risk individuals are 36 and 123 months, respectively (OR, 15.55; 95% confidence interval, 3.81-63.36). Conclusions: We have identified a non-coding transcriptional signature predictor of survival and biomarker of relapse for stage I EOC. Clin Cancer Res; 23(9); 2356-66.

Published
2017

3. The epithelial-mesenchymal transition induced by keratinocyte growth conditions is overcome by E6 and E7 from HPV16, but not HPV8 and HPV38: characterization of global transcription profiles. [*Azzimonti B, *Dell'Oste V, co-first authors]

Author

Azzimonti, B, Dell'Oste, Valentina, Borgogna, C, Mondini, M, Gugliesi, Francesca, DE ANDREA, Marco, Chiorino, G, Scatolini, M, Ghimenti, C, Landolfo, Santo Giuseppe, and Gariglio, M.

Subjects
Keratinocytes, HPV, FAD medium, Epithelial–mesenchymal transition, Microarray, Transcriptional profile
Published
2009

4. Characterization of the 20S proteasome in human glioblastomas

Author

Piccinini M, Mt, Rinaudo, Anselmino A, Cristina RAMONDETTI, Buccinnà B, Fiano V, Ghimenti C, and Schiffer D

Subjects
Central Nervous System Neoplasms, Cysteine Endopeptidases, Proteasome Endopeptidase Complex, Multienzyme Complexes, Macrophages, Humans, Lymphocytes, Microglia, Glioblastoma, Immunohistochemistry, Peptide Hydrolases
Abstract

Proteasomes are multisubunit proteases involved in many cellular processes, including tumorigenesis and immune surveillance. In their catalytic core, the 20S proteasome, the beta1, beta2 and beta5 subunits show peptidylglutamyl peptide hydrolyzing (PGPH), trypsin-like and chymotrypsin-like activities, respectively. By IFN-gamma and TNFalpha stimulus, these subunits are replaced by their counterparts LMP2, MECL-1 and LMP7, defined inducible subunits, thus originating the immunoproteasome, and expression of the proteasome activator PA28 is enhanced. These modifications strengthen MHC-class I restricted peptide generation. The 20S proteasome has been detected immunohistochemically in formalin-fixed samples purified from fresh surgical specimens of 18 tumors (G20S) and from 8 samples of normal peritumoral tissue. The G20S, LMP2, MECL-1 and LMP7 increased in only 12 cases, along with unvaried trypsin-like and decreased PGPH and chymotrypsin-like activities; PA28 was unvaried in all 18 samples. The immunoproteasome alterations may represent an anomalous immunological attitude of glioblastomas.

Published
2005

6. Deregulation of the p14ARF/Mdm2/p53 pathway and G1/S transition in two glioblastoma sets

Author

Ghimenti, C., Fiano, Valentina, CHIADO'-PIAT, Loredana, Chio', Adriano, Cavalla, P., and Schiffer, Davide

Subjects
Brain Neoplasms, DNA Mutational Analysis, Glioblastoma, proliferazione, G1 Phase, Nuclear Proteins, Proto-Oncogene Proteins c-mdm2, Exons, DNA Methylation, S Phase, Immunoenzyme Techniques, Proto-Oncogene Proteins, Glial Fibrillary Acidic Protein, Tumor Suppressor Protein p14ARF, Tumor Cells, Cultured, Humans, Gene Silencing, Tumor Suppressor Protein p53, Cyclin-Dependent Kinase Inhibitor p16, Sequence Deletion
Abstract

Sixty-one glioblastomas have been studied, subdivided into the categories of classic glioblastomas (GBM) and glioblastomas with astrocytic (GBA) and oligodendroglial (GBO) differentiated areas. On surgical samples, TP53, Mdm2, CDKN2A/p16-p14 alterations were studied by molecular biology techniques and by immunohistochemistry. It has been found that Mdm2 amplification was more frequent in GBM than in GBA and GBO, that p14ARF was inactivated in a high percentage of cases in the three tumor categories. Both these and other alterations did not reach a statistical significance, with the exception of CDKN2A/p16 homozygous deletion which showed the highest frequency in GBO. The latter finding could be in line with the observation that CDKN2A/p16 inactivation is a step in the molecular pathway to tumor progression in oligodendrogliomas. TP53 mutations and Mdm2 amplifications were mutually exclusive, whereas TP53 mutations and CDKN2A/p14 inactivation coexisted in 5 cases. The alterations of the p53/Mdm2/p14ARF pathway occurred in 73% of cases and in 80% of cases if CDKN2A homozygous deletions were associated. All glioblastomas with gemistocytic areas showed p14ARF inactivation. Immunohistochemistry showed higher percentages of positivity in comparison with molecular genetics, but with similar variations.

Published
2003

10. Different expressivity of BRCA1 and BRCA2: analysis of 179 Italian pedigrees with identified mutation RID A-1110-2010

Author

Aretini, P, D'Andrea, E, Pasini, B, Viel, A, Costantini, Rm, Cortesi, L, Ricevuto, E, Agata, S, Bisegna, R, Boiocchi, M, Caligo, Ma, Chieco Bianchi, L, Cipollini, G, Crucianelli, R, D'Amico, C, Federico, M, Ghimenti, C, De Giacomi, C, De Nicolo, A, Della Puppa, L, Ferrari, S, Ficorella, C, Iandolo, D, Manoukian, S, Marchetti, P, Marroni, F, Menin, C, Montagna, M, Ottini, L, Pensotti, V, Pierotti, M, Radice, P, Santarosa, M, Silingardi, V, Turchetti, D, Bevilacqua, G, and Presciuttini, Silvano

Published
2003

34. Microsatellite instability in human cancer

Author

Ghimenti, C, Caligo, Ma, Marchetti, A, Buttitta, F, Campani, Daniela, Pellegrini, Silvia, Lonobile, A, Giulianotti, Pc, Boggi, Ugo, Fornaciari, Gino, and Bevilacqua, Generoso

Subjects
instability, Microsatellites
Published
1995

36. Instabilità genomica in carcinomi del Pancreas

Author

Caligo, Ma, Ghimenti, C, Giulianotti, Pc, Boggi, Ugo, Giardino, D, Mosca, Franco, Bevilacqua, Generoso, and Fornaciari, Gino

Subjects
microsatelliti, genomica, instabilità
Published
1994

39. Microsatellite Instability in Pancreatic Cancer

Author

Fornaciari, Gino, Caligo, Ma, Ghimenti, C, Giulianotti, Pc, Boggi, Ugo, Balestracci, T, Giardino, D, and Mosca, Franco

Subjects
instability, pancreas cancer, Microsatellites
Published
1994

47. Mutation Analysis of BRCA1 and BRCA2 in Italian Hereditary and Sporadic Forms of Breast and Ovarian Cancers: Tumor Genotype-Phenotype Correlation in Breast Cancer BRCA-Mutation Carriers

Author

Cipollini, G., primary, Ghimenti, C., additional, Sensi, E., additional, Iandolo, D., additional, Piccirilli, A., additional, Berti, A., additional, Naccarato, G., additional, Viacava, P., additional, Campani, D., additional, Bevilacqua, G., additional, and Caligo, M. A., additional

Published
1999
Full Text
View/download PDF

49. BRCA 1 germline mutational spectrum in 21 Italian families

Author

Caligo, M.A., primary, Ghimenti, C., additional, Cipollini, G., additional, Ricci, S., additional, Brunetti, I., additional, Marchetti, V., additional, Shattuck-Eidens, D., additional, Conte, P.F., additional, Skolnick, M., additional, and Bevilacqua, G., additional

Published
1996
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results